More success for immunotherapy with nivolumab approval for metastatic RCC

Article Type

Changed

Fri, 01/04/2019 - 11:12

Display Headline

Author(s)

Following its recent success in non–small-cell lung cancer (NSCLC), the immunotherapeutic agent nivolumab received approval from the US Food and Drug Administration last fall for the treatment of advanced clear-cell renal-cell carcinoma (RCC) after prior antiangiogenic therapy. Nivolumab, an immune checkpoint inhibitor, is a fully human immunoglobulin G4 monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor on the surface of T cells, prevents their inactivation by tumor cells overexpressing PD-1 ligands, and helps to reinstate the anti-tumor immune response.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_apr_138_Abraham.pdf

Issue

The Journal of Community and Supportive Oncology - 14(4)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Genitourinary Cancer

Immunotherapy

Page Number

138-140

Legacy Keywords

renal cell carcinoma, RCC, immunotherapy, nivolumab, CheckMate-025, programmed death cell

Sections

Community Translations

Author(s)

Edited Jame Abraham

Author(s)

Edited Jame Abraham

Article PDF

JCSO_apr_138_Abraham.pdf

Article PDF

JCSO_apr_138_Abraham.pdf

Following its recent success in non–small-cell lung cancer (NSCLC), the immunotherapeutic agent nivolumab received approval from the US Food and Drug Administration last fall for the treatment of advanced clear-cell renal-cell carcinoma (RCC) after prior antiangiogenic therapy. Nivolumab, an immune checkpoint inhibitor, is a fully human immunoglobulin G4 monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor on the surface of T cells, prevents their inactivation by tumor cells overexpressing PD-1 ligands, and helps to reinstate the anti-tumor immune response.

Click on the PDF icon at the top of this introduction to read the full article.

Following its recent success in non–small-cell lung cancer (NSCLC), the immunotherapeutic agent nivolumab received approval from the US Food and Drug Administration last fall for the treatment of advanced clear-cell renal-cell carcinoma (RCC) after prior antiangiogenic therapy. Nivolumab, an immune checkpoint inhibitor, is a fully human immunoglobulin G4 monoclonal antibody that binds to the programmed cell death 1 (PD-1) receptor on the surface of T cells, prevents their inactivation by tumor cells overexpressing PD-1 ligands, and helps to reinstate the anti-tumor immune response.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 14(4)

Issue

The Journal of Community and Supportive Oncology - 14(4)

Page Number

138-140

Page Number

138-140

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology